[Comment] Fundamental PEPFAR Reform Risks a Period of Structural Vulnerability in the HIV Response

Why It Matters

Without stable U.S. financing, the global HIV response risks losing critical gains, threatening both donor‑dependent programs and broader public‑health objectives.

Key Takeaways

• US Congress hasn't reauthorized PEPFAR for FY 2026
• Funding cuts jeopardize HIV prevention and treatment programs
• Kenya and South Africa face service gaps without US aid
• New “America First” strategy shifts focus to bilateral agreements
• Structural reforms risk long‑term sustainability of global HIV response

Pulse Analysis

PEPFAR has been a cornerstone of the global HIV fight since its 2003 launch, channeling billions of dollars into treatment, testing, and prevention across sub‑Saharan Africa. The program’s recent funding hiatus—triggered by a stalled reauthorization and a strategic pivot toward bilateral agreements—has disrupted the predictable cash flow that ministries of health and NGOs rely on for procurement and service delivery. This uncertainty arrives at a time when the HIV epidemic still accounts for over 1.5 million new infections annually, making stable financing essential for maintaining treatment cascades and scaling innovative interventions such as long‑acting PrEP.

The immediate impact of the reforms is already visible on the ground. In Kenya, the discontinuation of the DREAMS initiative has left adolescent girls with fewer prevention options, while South Africa reports shortages of antiretroviral drugs and reduced outreach for key populations. Modeling studies suggest that a 20 percent cut in PEPFAR’s pre‑exposure prophylaxis budget could increase new infections by up to 150,000 cases in the next two years. These service gaps underscore how quickly funding volatility translates into public‑health setbacks, especially in countries where external aid constitutes a majority of HIV program budgets.

Looking ahead, the sustainability of the HIV response hinges on diversifying financing sources and rebuilding multilateral coordination. Donor nations, private foundations, and emerging economies must fill the vacuum left by reduced U.S. contributions, while host governments need to strengthen domestic health financing and integrate HIV services into broader health systems. Policy advocates call for a swift congressional reauthorization of PEPFAR or, at minimum, a clear transition plan that safeguards core services. Until such measures are in place, the global community faces a precarious window where structural vulnerability could reverse decades of progress toward epidemic control.